Education
About Us
Working with TipRanks
Follow Us
Caris Life Sciences, Inc. (CAI)
:CAI
RESEARCH TOOLSreports
CAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.40 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)713.93K
Market Cap
$10.80B
Enterprise Value$7.21B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 12, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 09, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding281,224,120
10 Day Avg. Volume1,017,826
30 Day Avg. Volume713,933
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$37.89Price Target Upside-1.30% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
EarningsCAI's first quarter since the IPO was materially ahead of consensus expectations, with stronger pricing and better volumes.
Market PositionCaris Life Sciences is a rapidly-growing market leader in precision oncology lab testing.
Revenue GrowthRevenue of $181.4M well exceeded expectations, growing 81%, with both volumes and Pharma R&D contributing to the strong quarter.
Bears Say
Profitability ConcernsA High Risk rating is assigned due to the current lack of profitability and early-stage commercial payer conversations for rate increases, leading to stock volatility.
Stock VolatilityCaris is trading at a premium valuation due to its strong financial profile and near-term path to profitability.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $25.40 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $10.80B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 12, 2025 which is 16 days ago.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Aug 12, 2025. The company reported -$7.97 earnings per share for the quarter, missing the consensus estimate of -$0.218 by -$7.752.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Overvalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 281,224,120 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of -$7.97 in its last earnings report, missing expectations of -$0.218. Following the earnings report the stock price went up 5.607%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
Caris Life Sciences, Inc. Stock Smart Score
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q2 2025
0:00 / 0:00
CAI Stock 12 Month Forecast
Average Price Target
$37.89
▼(-1.30% Downside)
Technical Analysis
IN8bio
―
MSP Recovery
―
NLS Pharmaceutics
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Ownership Overview
70.60% Insiders
0.31% Mutual Funds
25.73% Other Institutional Investors
3.19% Public Companies and
Individual Investors